Upgrade to SI Premium - Free Trial

AstraZeneca (AZN) Shares Plunge After MYSTIC Trial Did Not Meet Primary Endpoint

July 27, 2017 5:49 AM
AstraZeneca (NYSE: AZN) shares are plunging 16% in pre-open trade after the company announced progression-free survival (PFS) results for the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

FDA Hot FDA News Trader Talk

Next Articles